PB2699: CONSENSUS FROM AN EXPERT PANEL ON THE CURRENT MANAGEMENT OF SECONDARY IMMUNODEFICIENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN SPAIN

Autor: Concepción Boqué, Silvia Sánchez-Ramón, Raul Cordoba, Carol Moreno, Elena Cabezudo Perez

Publikováno v: HemaSphere, Vol 7, p e351524a (2023)

Externí odkaz: https://doaj.org/article/b65f0cd42e0a493e993c5cac88dac1f3

Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study

Autor: Rosanne Janssens, Tamika Lang, Ana Vallejo, Jayne Galinsky, Ananda Plate, Kate Morgan, Elena Cabezudo, Raija Silvennoinen, Daniel Coriu, Sorina Badelita, Ruxandra Irimia, Minna Anttonen, Riikka-Leena Manninen, Elise Schoefs, Martina Vandebroek, Anneleen Vanhellemont, Michel Delforge, Hilde Stevens, Steven Simoens, Isabelle Huys

Publikováno v: Frontiers in Medicine, Vol 8 (2021)

Background: Investigational and marketed drugs for the treatment of multiple myeloma (MM) are associated with a range of characteristics and uncertainties regarding long term side-effects and efficacy. This raises questions about what matters most to

Externí odkaz: https://doaj.org/article/2f7a9f0125f74320923fd8baca99dce4

Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Autor: Bruno Paiva, Jesus F. San-Miguel, Aldo M. Roccaro, Hervé Avet-Loiseau, Hartmut Goldschmidt, Alberto Orfao, Juan Flores-Montero, Maria-Victoria Mateos, Noemi Puig, Pablo Rios, Maria Sarasa, Luis Palomera, José-Ángel Hernández-Rivas, Javier de la Rubia, Albert Oriol, Maialen Sirvent, Valentin Cabañas, Adrian Alegre, Maria Casanova, Antoni Garcia-Guiñon, Heinz Ludwig, Felipe De Arriba, Clara Gomez, Helena Vitoria, Catarina Geraldes, Artur Paiva, Rebeca Iglesias, Fernando Solano, Joaquin Martinez-Lopez, Roman Hájek, Enrique M. Ocio, Maria-Elena Cabezudo, Joan Bargay, Felipe Prosper, Luis-Esteban Tamariz-Amador, Aitziber Lopez, Juan-Jose Garces, Cirino Botta, Camilla Guerrero, Esperanza Martín-Sánchez, Catarina Maia, Cristina Perez, Cristina Moreno, Sara Rodriguez, Alessandra Tucci, Viviana Giustini, Marco Chiarini, Antonio Sacco, Francois Vergez, Jill Corre, Anna Luise Grab, Elias K. Mai, Niels Weinhold, Marc Raab, Tomáš Jelínek, Albert Perez-Montaña, Evangelos Terpos, David Žihala, Rosalinda Termini

Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eaff79e65607faf2694fefda8986581
https://doi.org/10.1158/1078-0432.22489136

Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Autor: Bruno Paiva, Jesus F. San-Miguel, Aldo M. Roccaro, Hervé Avet-Loiseau, Hartmut Goldschmidt, Alberto Orfao, Juan Flores-Montero, Maria-Victoria Mateos, Noemi Puig, Pablo Rios, Maria Sarasa, Luis Palomera, José-Ángel Hernández-Rivas, Javier de la Rubia, Albert Oriol, Maialen Sirvent, Valentin Cabañas, Adrian Alegre, Maria Casanova, Antoni Garcia-Guiñon, Heinz Ludwig, Felipe De Arriba, Clara Gomez, Helena Vitoria, Catarina Geraldes, Artur Paiva, Rebeca Iglesias, Fernando Solano, Joaquin Martinez-Lopez, Roman Hájek, Enrique M. Ocio, Maria-Elena Cabezudo, Joan Bargay, Felipe Prosper, Luis-Esteban Tamariz-Amador, Aitziber Lopez, Juan-Jose Garces, Cirino Botta, Camilla Guerrero, Esperanza Martín-Sánchez, Catarina Maia, Cristina Perez, Cristina Moreno, Sara Rodriguez, Alessandra Tucci, Viviana Giustini, Marco Chiarini, Antonio Sacco, Francois Vergez, Jill Corre, Anna Luise Grab, Elias K. Mai, Niels Weinhold, Marc Raab, Tomáš Jelínek, Albert Perez-Montaña, Evangelos Terpos, David Žihala, Rosalinda Termini

Purpose:Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor cells (CTC), and adding im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269e3901fcebe2c362eb0cef18a3dbdc
https://doi.org/10.1158/1078-0432.c.6532880

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

Autor: David F. Moreno, Victoria Clapés, Juan Alfons Soler, Yolanda González-Montes, Mercedes Gironella, Cristina Motlló, Miquel Granell, Eugenia Abella, Marta García-Pintos, Antoni García-Guiñón, Elena Cabezudo, Joan Bladé, Laura Rosiñol

Publikováno v: Clinical Lymphoma Myeloma & Leukemia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Introduction: Daratumumab is an anti-CD38 agent that was first investigated as single agent in GEN501 and SIRIUS trials in patients with advanced multiple myeloma (MM). Overall response rate (ORR) was 30% with positive impact on progression-free surv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f05bd78bc8fc61b502d6acd72ea33bbe
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12297